Ki-S1 - A Prognostic Marker for Hypopharyngeal Carcinoma with Potential Predictive Value for Response to Chemotherapy

Anticancer Research

Volumn 23, Issue 5 A, 2003, Pages 3965-3970

  Kuropkat, Christiane ^a   Rudolph, Pierre ^b   Parwaresch, Reza ^b   Werner, Jochen A ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Head and neck; Monoclonal antibody; Multidrug resistance; Proliferation; Squamous cell carcinoma; Tumor marker

Indexed keywords

BIOLOGICAL MARKER; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY LABELING; ARTICLE; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; CONTROLLED STUDY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; EPITOPES; FEMALE; HUMANS; HYPOPHARYNGEAL NEOPLASMS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 0344874072     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Ho CM, Lam KH, Wie WI, Yuen PW and Lam LK: Squamous cell carcinomas of the hypopharynx-analysis of treatment results. Head and Neck 15: 405-412, 1993.
2. Kuropkat C, Rudolph P, Frahm SO, Parwaresch R and Werner JA: Proliferation marker Ki-S11 - a prognostic indicator for squamous cell carcinoma of the hypopharynx. Virch Arch 435: 590-595, 1999.
3. Jones AS: The management of early hypopharyngeal cancer: primary radiotherapy and salvage surgery. Clin Otolaryngol 17: 545-549, 1992.
4. Alvi A and Johnson JT: Extracapsular spread in the clinically negative neck (NO): implications and outcome. Otolaryngol Head Neck Surg 114: 65-70, 1996.
5. Steiner W: Therapy of hypopharyngeal cancer. Part I. Review of literature: surgery and/or radiotherapy. HNO 42: 4-13, 1994.
6. Gerdes J, Dallenbach F, Lennert K, Lemke H and Stein H: Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined-in situ with the monoclonal antibody Ki-67. Hematol Oncol 2: 365-371, 1984.
7. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E and Flad HD: Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138: 867-873, 1991.
8. Schwarting R: Little missed markers and Ki-67. Lab Invest 68: 597-599, 1993.
9. Brown DC and Gatter KC: Ki67 protein: the immaculate deception? Histopathol 40: 2-11, 2002.
10. Rudolph P, Heidebrecht HJ, Kellner U, Seidel A and Parwaresch R: Proliferation marker Ki-S1 binds to a formalin-resistant epitope of topoisomerase II. Int J Surg Pathol 2: 388, 1995.
11. Rudolph P, Olson H, Bonatz G, Ratjen V, Bolte H, Baldetorp B, Fernö M, Parwaresch R and Alm P: Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status, and proliferation in 356 node-negative ductal invasive carcinomas of the breast: prognostic implications. J Pathol 187: 207-216, 1999.
12. Kellner U, Heidebrecht HJ, Rudolph P, Biersack H, Buck F, Dakowski T, Wacker HH, Domanowski M, Seidel A, Westergaard O and Parwaresch R: Detection of topoisomerase II in cell lines and tissues: characterization of five novel monoclonal antibodies. J Histochem Cytochem 45: 1-13, 1997.
13. Kellner U, Sehested M, Jensen PB, Gieseler F and Rudolph P: Culprit and victim-DNA topoisomerase II. Lancet Oncol 3: 235-243, 2002.
14. Unemura T, Ohkura H, Yasuhisa A, Morino K, Shiozaki K and Yanagida M: DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell 50: 917-925, 1987.
15. Tsutsui K, Okada S, Watanabe M, Shohmori T, Seki S and Inoue Y: Molecular cloning of partial cDNAs for rat DNA topoisomerase II isoforms and their differential expression in brain development. J Biol Chem 268: 1976-1983, 1993.
16. Stathopoulos GP, Kapranos N, Manolopoulos L, Papadimitriou C and Adan G: Topoisomerase II alpha expression in squamous cell carcinoma of the head and neck. Anticancer Res 20: 177-182, 2000.
17. Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375, 1989.
18. Wilson CS, Medeiros LJ, Lai R, Butch AW, McCourty A, Kelly K and Brynes RK: DNA topoisomerase II alpha in multiple myeloma: a marker of cell proliferation and not drug resistance. Mod Pathol 14: 886-891, 2001.
19. MacGrogan G, Rudolph P, de Mascarel I, Mauriac L, Durand M, Avril A, Dilhuydy JM, Robert J, Mathoulin-Pélissier S, Picot V, Floquet A, Sierankowski G and Coindre JM: Predictive and prognostic value of the immunhistochemical detection of topoisomerase IIα for the response to primary chemotherapy in patients with breast cancer. Int J Cancer, in press.
20. Sampson SA, Kreipe H, Gillett CE, Smith CE, Smith P, Chaundary MA, Khan A, Wicks K, Parwaresch MR and Barnes DM: Ki-S1 a novel monoclonal antibody which recognizes proliferating cells: evaluation of its relationship to prognosis in mammary carcinoma. J Pathol 168: 179-185, 1992.
21. Kreipe H, Alm P, Olsson H, Hauberg M, Fischer L and Parwaresch R: Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1. Am J Pathol 142: 651-657, 1993.
22. Kreipe H, Wacker HH, Heidebrecht HJ, Haas K, Hauberg M, Tiemann M and Parwaresch R: Determination of the growth fraction in non-Hodgkin's lymphomas by monoclonal antibody Ki-S5 directed against a formalin-resistant epitope of the Ki-67 antigen. Am J Pathol 142: 1689-1694, 1993.
23. Heidebrecht HJ, Buck F, Haas K, Wacker HH and Parwaresch R: Monoclonal antibodies Ki-S3 and Ki-S5 yield new data on the 'Ki-67' protein. Cell Prolif 29: 413-425, 1996.
24. Rudolph P, Kellner U, Chassevent A, Collin F, Bonichon F, Parwaresch R and Coindre JM: Prognostic relevance of a novel proliferation marker, Ki-S11, for soft tissue sarcoma. A multivariate study. Am J Pathol 150: 1997-2007, 1997.
25. Rudolph P, Knfichel R, Endl E, Heidebrecht HJ, Hofstädter F and Parwaresch R: The immunohistochemical marker Ki-S2: tissue distribution and cell cycle kinetics of a novel proliferation-specific antigen. Mod Pathol 11: 450-456, 1998.
26. Shi SR, Key ME and Kalra KL: Antigen-retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39: 741-748, 1991.
27. Koehler G and Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497, 1975.
28. Boege F, Andersen A, Jensen S, Zeidler R and Kreipe H: Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies. Am J Pathol 146: 1302-1308, 1995.
29. Hsu SM, Raine L and Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577-580, 1981.
30. Sigurdsson H, Baldetorp B, Borg A, Dalberg M, Ferno M, Killander D, Olsson H and Ranstam J: Flow cytometry in primary breast cancer: improving the prognostic value of the fraction of cells in S-phase by optimal categorization of cut off levels. Br J Cancer 62: 786-790, 1990.
31. Rudolph P, MacGrogan G, Bonichon F, Frahm SO, de Mascare I, Trojani M, Durand M, Avril A, Coindre JM and Parwaresch R: Prognostic significance of Ki-67 and topoisomerase II alpha expression in infiltrating ductal breast cancer. A multivariate analysis of 863 cases. Breast Cancer Res Treat 55: 61-71, 1999.
32. Witthoff S, De Jong S, De Vries EG and Mulder NH: Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review). Anticancer Res 16: 1867-1880, 1996.
33. Dalton WS, Grogan RM, Rybski JA, Scheper RJ, Richter L and Kailey J: Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood 73: 747-752, 1989.
34. Gupta V, Singh SV, Ahmad H, Medh RD and Awasthi YC: Glutathione and glutathione S-transferase in a human plasma cell line resistant to melphalan. Biochem Pharmacol 38: 1993-2000, 1989.
35. Huuhtanen RL, Wiklund TA, Blomqvist CP, Bohling TO, Virolainen MJ, Tribukait B and Andersson LC: A high proliferation rate measured by cyclin A predicts a favorable chemotherapy response in soft tissue sarcoma patients. Br J Cancer 81: 1017-1021, 1999.
36. 1 checkpoint control induced by coculture of prostate cancer cells with osteoblasts. Cancer Res 61: 6372-6376, 2001.
37. Sjöström J, Blomqvist C, Heikkilä P, von Boguslawski K, Räisänen-Sokolowski A, Bengtsson NO, Mjaaland I, Malmström P, Ostenstadt B, Bergh J, Wist E, Valvere V and Saksela E: Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 6: 3103-3110, 2000.
38. Coon JS, Marcus E, Gupta-Burt S, Seeling S, Jacobson K, Chen S, Renta V, Fronda G and Preisler HD: Amplification and overexpression of topoisomerase IIα predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 8: 1061-1067, 2002.
39. Kohno N, Ichikawa G, Nakazawa E, Kusunoki M and Nishiya M: Induction chemotherapy with cisplatin, etoposide, and mitomycin-C (PEM) regimen in advanced cases with cancer of pharynx and oral cavity. Auris Nasus Larynx 22: 49-52, 1995.
40. Kohno N, Ichikawa G, Shirasaka T, Inuyama Y, Kawaida M and Ohnuma T: Salvage chemotherapy with PEM and long CF regimen in CDDP refractory advanced head and neck cancer. Gan To Kagaku Ryoho 22 Suppl 3: 209-214, 1995.
41. Cornarotti M, Caprianico G, Bohm S, Oriana S, Spatti GB, Mariani L, Ballabio G and Zunino F: Gene expression of DNA topoisomerase I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Int J Cancer 67: 479-484, 1996.
42. Koshiyama M, Fujii H, Kinezaki M and Yoshida M: Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas. Anticancer Res 21: 905-910, 2001.
43. Dingemans AM, Witlox MA, Stallaert RA, van der Valk P, Postmus PE and Giaccone G: Expression of DNA topoisomerase II alpha and topoisomerase II beta genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin Cancer Res 5: 2048-2058, 1999.
44. Haller J, Burgess R and Dawson D: Increased cytotoxicity of squamous cell carcinoma of the head and neck by combining cisplatin with VP-16 and ciprofloxacin. Laryngoscope 103: 1081-1083, 1993.
45. Polee MB, Kok TC, Siersema PD, Tilanus HW, Splinter TA, Stoter G and van der Gaast A: Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus. Anticancer Drugs 12: 513-517, 2001.